Where does Jiangsu Hengrui Medicine Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Jiangsu Hengrui Medicine Co., Ltd. ranks #2,791 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Jiangsu Hengrui Medicine Co., Ltd. hold?

Jiangsu Hengrui Medicine Co., Ltd. holds 138 US utility patents granted between 2015 and 2025, spanning 16 technology areas.

What is Jiangsu Hengrui Medicine Co., Ltd.'s Innovation Score?

Jiangsu Hengrui Medicine Co., Ltd. has an Innovation Score of 44.3 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Jiangsu Hengrui Medicine Co., Ltd. focus on?

Jiangsu Hengrui Medicine Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 128 patents, ranking #117 of 6,058 assignees active in that subclass. Grants appear in 16 CPC subclasses total.

Is Jiangsu Hengrui Medicine Co., Ltd.'s patent grant rate increasing or decreasing?

Jiangsu Hengrui Medicine Co., Ltd.'s recent grant velocity is +84% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Jiangsu Hengrui Medicine Co., Ltd.'s patents?

Jiangsu Hengrui Medicine Co., Ltd.'s patents average 16.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Jiangsu Hengrui Medicine Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Jiangsu Hengrui Medicine Co., Ltd.

USPTO PatentsView assignee record - 138 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Jiangsu ranks #2,791 of 49,997 tracked US assignees by granted-patent volume, with 138 patents across 16 technology areas.

#2,791
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.3/100): 16.5
avg claims per patent: +84%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2791 · Foreign Corporation #2,791 · 138 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MID 138 grants
TOP-DECILE #2,791/49,997
PHOTO-FINISH Dell Software
CPC-FOCUS A61P · 16 areas
INNOV-PAR 44.3/100
CLAIMS-RICH 16.5 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +84% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Dell Software Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Jiangsu’s 44.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 17.0 pts (38%) Velocity 3.2 pts (7%) Breadth 14.1 pts (32%) Claim depth 9.9 pts (22%)

Qualcomm Incorporated · highest

85
Bic-violex · near

44
Fluence Bioengineering · near

44
H J Heinz Brands · near

44
Heathco · near

44
Jiangsu Hengrui… · this assignee

44
3D Lighting… · lowest

7

What this shows Jiangsu's Innovation Score is 44.3/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Jiangsu?

Each dot is one of Jiangsu’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Jiangsu’s own 16.5 claims/patent is at or below the 17.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Jiangsu vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Jiangsu's grants concentrate

Jiangsu Hengrui Medicine Co., Ltd. is a focused PatentsView assignee: 16 CPC subclasses with 92.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (29 grants) versus a trough of 2 in 2015. By volume, Jiangsu sits between Dell Software Inc. and RTC Industries, Inc..

Jiangsu's three-year grant acceleration

From 2019–2021 to 2022–2024, Jiangsu Hengrui Medicine Co., Ltd. moved from 64 to 31 grants (0.48x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,731. See the growth leaderboard.

Dell Software

138
Dynamics

138
Feit Electric

138
Fuzhou BOE Optoel…

138
Lubrizol Advanced…

138
Multivac Sepp Hag…

138
Qiagen

138
RTC Industries

138
Jiangsu Hengrui M… ◀

138

What this shows Jiangsu holds 138 patents at rank #2,791, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Jiangsu

By rank, the assignees closest to #2,791 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Jiangsu's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Jiangsu, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Jiangsu ranks #117 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Bic-violex SA 44 H.J. Heinz Company Brands LLC 44 Fluence Bioengineering, Inc. 44 Heathco LLC 44

Similar claim depth

Nearest assignees by average claims per patent (16.5 here).

Honeywell International Inc. 16.5 avg GE Global Sourcing LLC 16.5 avg North Atlantic Imports, LLC 16.5 avg Spinal Elements, Inc. 16.5 avg

Jiangsu's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Jiangsu Hengrui Medicine Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	1.4%
2016	8	5.8%
2017	2	1.4%
2018	15	10.9%
2019	16	11.6%
2020	19	13.8%
2021	29	21.0%
2022	23	16.7%
2023	4	2.9%
2024	4	2.9%
2025partial year	16	11.6%

Which technologies does Jiangsu Hengrui Medicine Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 128

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 109

C07D - Heterocyclic Compounds 77

C07K - Peptides 40

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 18

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 10

C07C - Acyclic OR Carbocyclic Compounds 9

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 7

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

Y02A - Technologies FOR Adaptation TO Climate Change 5

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

B29C - Shaping OR Joining OF PLASTICS; Shaping OF Material IN A Plastic State, NOT Otherwise Provided FOR; After-treatment OF THE Shaped Products, e.g. Repairing 1

Top 15 of 16 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Jiangsu Hengrui Medicine Co., Ltd.'s patent record in context - here's where to go next.

Jiangsu Hengrui Medicine Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #2,791 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Jiangsu Hengrui Medicine Co., Ltd. against Dell Software Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.